Search the Newsreel

BioNexus Gene Lab names CFO Chong Set Fui in initial beneficial ownership filing

BioNexus Gene Lab has filed an initial Form 3 for its CFO, Chong Set Fui, dated June 17, 2025. This news brief was generated by Public Technologies using AI and is for informational purposes only, not financial advice. The original content was published via …

BioNexus Gene Lab (BGLC) CEO files Form 3 showing 0.0000 shares

BioNexus Gene Lab Corp (BGLC) CEO and director Tan Lee Su-Leng filed a Form 3, an initial statement of beneficial ownership of securities, reporting 0.0000 shares held directly. This filing, dated August 15, 2023, indicates no buy or sell transactions. The report clarifies that …

BioNexus Gene Lab Corp (BGLC) director reports holding 0 common shares

BioNexus Gene Lab Corp (BGLC) director Bin Abdul Hamid Muhammad Azrul filed a Form 3, an Initial Statement of Beneficial Ownership, reporting direct ownership of 0 shares of common stock as of December 11, 2023. The filing indicates no purchase, sale, or derivative transactions, …

Will Shinhan Bank Partnership in Korea Reshape StoneX Group's (SNEX) Cross-Border Payments Narrative?

StoneX Group's Payments Division has partnered with Shinhan Bank in South Korea to expand its cross-border payment and foreign exchange services across numerous currencies and countries. This collaboration is expected to deepen StoneX's presence in Asia-Pacific and emerging markets, potentially boosting transaction volumes but …

Euronext Athens Holding S.A. Revenue Breakdown – ATHEX:EXAE

Vanguard Portfolio Management (SNEX) discloses 5.14% beneficial stake in StoneX Group

Vanguard Portfolio Management LLC, along with its affiliates, has reported a 5.14% beneficial ownership stake in StoneX Group Inc., amounting to 4,075,393 shares. This disclosure, made via a SCHEDULE 13G SEC filing, indicates that Vanguard has sole voting power over 72,234 shares and sole …

Euronext NV (EUXTF) (Q2 2026) Earnings Call Highlights: Record Revenue and EBITDA Fueled by ...

This article first appeared on GuruFocus. Revenue: Record underlying revenue and income of EUR544.4 million, up 16.9% year-on-year. Adjusted EBITDA: Reached a record EUR360 million, up 21.1% year-on-year. Adjusted EBITDA Margin: 66.1%, an improvement of 2.3 percentage points compared to Q2 2025. Adjusted Net …

BioNexus Gene Lab Corp (BGLC) Financial Health: Profitability & Balance Sheet Analysis

BioNexus Gene Lab Corp (BGLC) has a current financial score of 6.04, ranking 292 out of 384 in the Biotechnology & Medical Research industry, indicating a robust financial status despite low operating efficiency. The company's latest quarterly revenue significantly decreased year-over-year by 98.93% to …

BioNexus Gene Lab Corp (BGLC) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for BioNexus Gene Lab Corp (BGLC), assigning it a score of 2.70 out of 384 companies in the Biotechnology & Medical Research industry. Key metrics include a beta value of 2.20, indicating higher volatility compared to the S&P …

Shinhan Bank Customers Expected to Gain Access to 140 Currencies

StoneX Payments has partnered with Shinhan Bank, South Korea's second-largest bank, to provide institutional-grade cross-border payment and FX services across over 140 currencies and 180 countries. This agreement gives Shinhan Bank access to StoneX's network of over 385 banks, enabling high-volume international transactions with …

StoneX Payments Announces Strategic Partnership with Shinhan Bank to Expand Cross-Border Payment and FX Services

StoneX Payments has partnered with Shinhan Bank to provide enhanced cross-border payment and foreign exchange services. This collaboration will give Shinhan Bank's clients access to StoneX's institutional-grade payment infrastructure, reducing transaction costs and settlement times across over 140 currencies in 180 countries. The partnership …

Shinhan Bank Selects StoneX Payments as Strategic Cross-Border Payments Partner

Shinhan Bank has partnered with StoneX Payments to enhance its cross-border payment services, offering institutional-grade FX execution across 140 currencies. This collaboration will provide Shinhan Bank's clients, including global importers, exporters, and multinational corporations, with reduced transaction costs, faster settlement times, and improved access …

StoneX Group Inc. to Announce 2026 Fiscal Third Quarter Earnings on August 5, 2026

StoneX Group Inc. (NASDAQ: SNEX) is scheduled to release its fiscal third-quarter earnings report for 2026 on August 5, 2026. The financial results will be announced before the market opens, followed by a conference call and webcast at 9:00 a.m. ET. Interested parties can …

Euronext publishes Q2 2026 results

Euronext Paris SA Euronext publishes Q2 2026 results Euronext delivers the ninth consecutive quarter of double-digit growth, with record results driven by the diversified business model and strategic execution. Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 30 July 2026 – Euronext, …

StoneX sets Aug. 6 conference call for fiscal Q3 results

StoneX Group (NASDAQ: SNEX) will release its fiscal 2026 third-quarter earnings after market close on Wednesday, August 5, 2026. Management will host a conference call on Thursday, August 6, 2026, at 9:00 a.m. Eastern Time to discuss the results, with webcast details available on …

StoneX's High ROE Supports the Bull Case: Is It Sustainable?

StoneX Group (SNEX) has shown a strong return on equity (ROE) of 19.31%, significantly above the industry average, driven by heightened market volatility, strategic acquisitions, and growing client balances. However, the sustainability of this high ROE is challenged by increasing expenses, rising bad-debt costs, …

Should Investors Consider StoneX Stock After Its Impressive YTD Rally?

StoneX Group's stock (SNEX) has surged 75.7% year-to-date, outperforming peers, due to a favorable environment for brokerage stocks, heightened volatility, and an uncertain macro backdrop. The company, which operates a diversified financial services franchise, has also benefited from strategic acquisitions and investments in AI-enabled …

StoneX Group (NASDAQ:SNEX) Insider Sells $3,892,584.32 in Stock

StoneX Group (NASDAQ:SNEX) insider Mark Lowry Maurer sold 52,376 shares of the company's stock for approximately $3.89 million on July 22nd, reducing his direct ownership by 19.21%. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The company's stock recently traded down …

StoneX Group (NASDAQ:SNEX) Insider Diego Rotsztain Sells 29,995 Shares

StoneX Group insider Diego Rotsztain sold 29,995 shares of SNEX stock for $2.23 million, reducing his position by 35.08% under a pre-arranged Rule 10b5-1 plan. This sale is part of a larger trend where StoneX insiders, including the chairman, CFO, and CEO, sold a …

StoneX Group (NASDAQ:SNEX) CFO Sells $7,133,450.10 in Stock

StoneX Group's CFO, William Dunaway, sold 95,970 shares of the company's stock for over $7.13 million, reducing his direct holdings by 16.89%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, StoneX shares have seen recent institutional inflows, and …

StoneX Group (SNEX) to Post Earnings on Tuesday

StoneX Group (SNEX) is scheduled to release its Q3 2026 earnings after market close on Tuesday, August 4th, with analysts expecting earnings of $0.857 per share and revenues of $1.321 billion. The company's previous quarter exceeded earnings estimates but missed revenue targets. Despite a …

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

BioNexus Gene Lab Corp. announced progress in commercializing its VitaGuard™ molecular residual disease (MRD) platform in Southeast Asia after a working visit to Tongshu Gene's facilities in China. The visit involved technical planning and meetings with Chinese hospitals where VitaGuard is already in commercial …

BioNexus Says VitaGuard Blood Tests Could Cost Under $300

BioNexus (BGLC) is progressing with the commercialization of its VitaGuard™ molecular residual disease (MRD) liquid-biopsy platform in Southeast Asia, targeting an initial rollout in select medical hubs in 2026. The company anticipates the cost per VitaGuard test to be under US$300, aiming to make …

StoneX Group (SNEX) legal chief sells 20,630 shares in plan trade

StoneX Group Inc.'s Chief Governance/Legal Officer, Diego Rotsztain, sold 20,630 shares of common stock on July 24, 2026, through a Rule 10b5-1 trading plan at an average price of $74.4007 per share. Following this transaction, Rotsztain retains 34,870 shares. The sale, valued at approximately …

Form 4 Stonex Group Inc For: 27 July By Investing.com

This article announces the filing of Form 4 for Stonex Group Inc. on July 27. It is a brief news item from Investing.com, accompanied by standard market data and links to related financial news and tools. The content primarily serves as a notification of …

Stonex chief governance officer sells $1.53m in stock

Diego Rotsztain, Chief Governance/Legal Officer at StoneX Group Inc. (NASDAQ:SNEX), sold 20,630 shares worth approximately $1.53 million on July 24, 2026. This insider sale follows a 77% surge in StoneX shares over the past year. The company recently surpassed earnings expectations but faced a …

BioNexus Gene Lab Corp Revenue Breakdown – NASDAQ:BGLC

BioNexus Gene Lab Corp (NASDAQ: BGLC) revenue breakdown highlights Malaysia as the primary contributor, generating $5.83 million last year, down from $7.46 million the previous year. This information is derived from their financial statements, focusing on top segments and regional performance.

SNEX|StoneX Group Inc|Price:74.260|Chg%:-0.600

This article provides a detailed introduction to StoneX Group Inc. (SNEX), outlining its global financial services network, business segments (Commercial, Institutional, Self-Directed/Retail, and Payments), and key financial data. It also lists company executives with their shareholdings and discusses institutional ownership, highlighting a significant increase …

BioNexus Gene Lab Corp (BGLC) Cash Flow

This article provides a detailed cash flow statement for BioNexus Gene Lab Corp (BGLC), including quarterly and annual data for operating, investing, and financing activities. It also defines key cash flow terms and offers insights into BGLC's financial health, such as an operating cash …

Noronex Acquires Advanced Alaska Tin-Tungsten-Silver Project

BioNexus Gene Lab Corp (BGLC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of BioNexus Gene Lab Corp (BGLC), including major individual and corporate holders, their proportionate ownership, and recent activity. It also provides institutional shareholding data over several quarters, showing changes in the number of institutions and shares held. Key …

Onex Corporation Revenue Breakdown – TSX:ONEX

Enterprise value to revenue forward of StoneX Group Inc. – NASDAQ:SNEX

This article from TradingView provides a financial overview of StoneX Group Inc. (NASDAQ: SNEX), specifically focusing on its enterprise value to revenue forward metric. It appears to be a stub or an introductory page for financial data, indicating that more detailed information might be …

BioNexus Gene Lab Corp (BGLC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of BioNexus Gene Lab Corp (BGLC), noting its current valuation score of 8.43, which ranks it 138 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -1.02, while also stating …

Stonex Group Inc. (SNEX) Q1 2025 Earnings Report - Results, Call & Slides

StoneX Group Inc. (SNEX) reported its Q1 2025 earnings, surpassing analyst expectations with an actual EPS of $13.18 against a consensus of $11.26 and actual revenue of $489.13 billion compared to an expected $16.02 billion. This represents a significant beat and a 42.71% year-over-year …

BGLC|BioNexus Gene Lab Corp|Price:1.510|Chg%:-0.050

BioNexus Gene Lab Corp (BGLC) is a biotechnology company specializing in precision diagnostics and chemical solutions. While the stock has seen significant declines over various periods, its fundamentals are deemed healthy with significant growth potential, and it is considered fairly valued within the Biotechnology …